Psychopharmacology Essays (Examples)
Study Document
Assessing And Treating Pediatric Clients With Mood Disorders
...Psychopharmacology Background
The client in the present scenario is an 8-year-old African American male who presents with signs of depression. Some of the reported symptoms include; feeling of sadness, occasional irritation, and decreased appetite. The score obtained upon the administration of the Children’s Depression Rating Scale indicates significant depression. This text concerns itself with three decisions relating to the medications prescribed for the 8-year-old.
Discussion
I. Zoloft
Decision Point 1: Begin Zoloft 25 mg orally daily
Studies conducted in the past have indicated that for children and adolescents suffering from depression, Zoloft (Sertraline) happens to be largely effective. According to Hritzak and Culhane (2004), “Sertraline (Zoloft) is effective and generally well tolerated for the short-term treatment of major depressive disorder in both children and adolescents” (17). In essence, Sertraline, which is essentially an SSRI, impacts unbalanced brain chemicals in persons suffering from anxiety disorders, panic disorders, as well as depression. Low……
References
References
American Academy of Pediatrics (2020). Sertraline - Zoloft (Oral Solution). Retrieved from https://www.aap.org/en-us/professional-resources/Psychopharmacology/Pages/Sertraline-Zoloft-Oral-Solution.aspx
Fainzang, S. (2011). Discourse on safe drug use: symbolic logics and ethical aspects. Drug Saf., 33(8), 623-629.
Hritzak, K. & Culhane, N.S. (2004). Sertraline effective for children and adolescents with major depression. J Fam Pract., 53(1), 8-14.
Milev, D.R. (2015). Does Sleep Quality Change after Switch from Wellbutrin SR to Wellbutrin XL in Patients with Major Depressive Disorder? Retrieved from https://clinicaltrials.gov/ct2/show/NCT00616915
Mullen, S. (2018). Major depressive disorder in children and adolescents. Ment Health Clin., 8(6), 275-283.
Navels, R.M., Gentkovsky, S.T. & Williams, B.E. (2016). Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacol Bull., 46(1), 77-104.
Patel, K., Allen, S., Haque, M.N., Angelescu, L., Baumeister, D. & Tracy, D.K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. The Adv Psychopharmacol., 6(2), 99-144.
Study Document
Autism Spectrum Disorder And Childhood Onset Schizophrenia
...Psychopharmacology Name: Article 1 Date:
Reference (APA Format)
Allen, A. R., & Pidano, A. E. (2017). Childhood Schizophrenia and Autism: An Empirical Study of Perceived Social Support. Journal of Child and Family Studies, 26(6), 1664-1670.
Theoretical Basis
A strong relationship has been established between social support and psychotic symptoms. However, there is not study that has analyzed the level of social support received by children with schizophrenia. Children who have low levels of social support have been found to be at a greater risk of increased internalizing and externalizing problems.
Hypothesis
Youth with childhood and adolescent schizophrenia would have less social support than children with autism spectrum disorder.
Children with the least amount of social support would report the lowest level of functioning
Independent Variables
Diagnosis and level of perceived functioning
Dependent Variables
Perceived social support
Control Groups
Children with Autism
Data Analysis & Statistical Methods
Tests used were the t-test……
References
Allen, A. R., & Pidano, A. E. (2017). Childhood Schizophrenia and Autism: An Empirical Study of Perceived Social Support. Journal of Child and Family Studies, 26(6), 1664-1670.
Jerrell, J. M., McIntyre, R. S., & Deroche, C. B. (2017). Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents. Human Psychopharmacology: Clinical and Experimental, 32(2), e2589.
Pina-Camacho, L., Parellada, M., & Kyriakopoulos, M. (2016). Autism spectrum disorder and schizophrenia: boundaries and uncertainties. BJPsych Advances, 22(5), 316-324.
Study Document
Huntington Disease Involving Oral Histology And Embryology
...Psychopharmacology Introduction
Huntington’s disease is one of many neurodegenerative diseases, which has chorea as one of its prevalent symptoms (Hergert, Sanchez-Ramos, & Cimino, 2019, p.1) . Discovered in the late 1800s’ by George Huntington, a young American medical doctor at the time, the disease has gathered interest from the medical community—but with little in the way of a cure. The disease is highly hereditary, with a 50% chance of transference from parent to offspring (Boyle, Frölander & Manley, 2008, p.333; Roos, 2010, p.6). This hereditary property (of this disease) is due to it being a genetic disorder, which is activated in those that exhibit its symptoms. Primarily, every person has the gene that causes Huntington’s disease, and the activation is equally likely in both biological classifications of human gender (Male and Female); however, those that activate its activity have the expanded version of the gene. For those with the defective gene, the……
References
References
Boyle, C. A., Frölander, C., & Manley, G. (2008). Providing Dental Care for Patients with Huntington’s Disease. Dental Update, 35(5), 333–336. doi:10.12968/denu.2008.35.5.333. Retrieved from: https://sci-hub.tw/https://doi.org/10.12968/denu.2008.35.5.333
Hergert, D. C., Sanchez-Ramos, J., & Cimino, C. R. (2019). Awareness of Chorea in Huntington’s Disease. Journal of Huntington’s Disease, 1–5. doi:10.3233/jhd-190381. Retrieved from: https://sci-hub.tw/10.3233/JHD-190381
Manley, G., Lane, H., Carlsson, A., Ahlborg, B., Mårtensson, Å., Nilsson, M. B., … Rae, D. (2012). Guideline for oral healthcare of adults with Huntington’s disease. Neurodegenerative Disease Management, 2(1), 55–65. doi:10.2217/nmt.11.68. Retrieved from: https://sci-hub.tw/https://doi.org/10.2217/nmt.11.68
McColgan, P., & Tabrizi, S. J. (2017). Huntington’s disease: a clinical review. European Journal of Neurology, 25(1), 24–34. doi:10.1111/ene.13413. Retrieved from: https://sci-hub.tw/https://doi.org/10.1111/ene.13413
Petersén, Å., & Weydt, P. (2019). The psychopharmacology of Huntington disease. Handbook of Clinical Neurology, 165(3), 179–189. doi:10.1016/b978-0-444-64012-3.00010-1. Retrieved from: https://sci-hub.tw/10.1016/B978-0-444-64012-3.00010-1
Rodríguez, M. L, Sánchez, V. E. (2015). Periodontitis determining the onset and progression of Huntington\\\\\\'s disease: review of the literature. Medwave, 15(9). doi:10.5867/medwave.2015.09.6293.
Roos, R. A. C. (2010). Huntington’s disease: a clinical review. Orphanet Journal of Rare Diseases, 5(1), pp.40-48. doi:10.1186/1750-1172-5-40. Retrieved from: https://sci-hub.tw/https://dx.doi.org/10.1186%2F1750-1172-5-40
Saft, C., Andrich, J. E., Müller, T., Becker, J., & Jackowski, J. (2013). Oral and dental health in Huntington‘s disease - an observational study. BMC Neurology, 13(1), 2-5. doi:10.1186/1471-2377-13-114. Retrieved from: https://sci-hub.tw/https://dx.doi.org/10.1186%2F1471-2377-13-114
Improve your studying and writing skills
We have over 150,000+ study documents to help you.
Sign Up for FREE
